News Releases

RNS Number : 4058S MaxCyte, Inc. 14 June 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Grant of Options and Restricted Stock Units   ROCKVILLE, MD , June 14, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Jun 14, 2024
RNS Number : 0511S MaxCyte, Inc. 12 June 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Results of AGM   Rockville, Maryland -   June 12 ,   2024:   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
Jun 12, 2024
RNS Number : 9400R MaxCyte, Inc. 11 June 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   PDMR Dealing   ROCKVILLE, MD , June 12, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
Jun 11, 2024
RNS Number : 9173Q MaxCyte, Inc. 03 June 2024   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights and Block Listing Return   ROCKVILLE, MD , June 3, 2024 :   MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT),   a leading, cell-engineering focused company providing enabling platform
Jun 03, 2024
RNS Number : 2809Q MaxCyte, Inc. 29 May 2024   MaxCyte to Participate in William Blair 44 th Annual Growth Stock Conference Rockville, MD , May 29, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
May 29, 2024
RNS Number : 4603P MaxCyte, Inc. 22 May 2024     4867-2449-5548v.1         MaxCyte   Signs   Strategic Platform License   Agreement with Legend Biotech   to Accelerate Cell Therapy Discovery and Development   Legend   Biotech obtains license   to use MaxCyte's Flow Electroporation® technology and
May 22, 2024
RNS Number : 0054P MaxCyte, Inc. 20 May 2024   TR-1: N otification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting
May 20, 2024
RNS Number : 4093O MaxCyte, Inc. 14 May 2024   TR-1: N otification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting
May 14, 2024